Collegium Pharmaceutical, Inc. COLL
22.53
(0.11)
(0.49%)
as of 25 Sep
- Market cap
- $737.1M
- P/E
- 14.7×
Follow COLL
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
18.91 | 23.15 | 13.95 | 23.66 |
P/S ratio |
1.46 | 1.88 | 1.33 | 1.45 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
14.08 | 11.93 | 18.58 | 16.48 | |
P/B ratio |
4.02 | 4.87 | 3.40 | 3.77 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.12 | 2.40 | 1.79 | 2.62 | |
EV/EBITDA |
4.21 | 4.62 | 3.44 | 5.42 | |
EV/Operating CF |
5.52 | 5.68 | 4.30 | 6.42 | |
EV/FCF |
(20.36) | (46.03) | (37.04) | (53.00) | |
Quick Ratio |
1.19 | 1.40 | 1.54 | 0.74 | |
Current Ratio |
1.36 | 1.57 | 1.71 | 1.03 | |
Net Debt/EBITDA |
4.24 | 3.45 | 4.17 | 13.77 | |
Debt/Assets |
50.28% | 48.85% | 48.60% | 51.11% | |
Debt/Equity |
2.94 | 2.68 | 2.57 | 3.50 | |
Asset Turnover |
0.47 | 0.47 | 0.49 | 0.43 | |
Operating CF/Net income |
2.49 | 7.25 | 3.94 | (4.74) | |
Capex/Depreciation |
0.00 | (0.01) | 0.00 | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
32.05% | 32.92% | 44.62% | 53.33% | |
Intangible Assets out of Total Assets |
0.54 | 0.49 | 0.46 | 0.64 | |
Share Based Compensation of Revenue |
4.69% | 4.75% | 5.62% | 7.25% | |
Graham Net Nets |
(0.65) | (0.45) | (0.56) | (1.03) | |
Graham Number |
19.03 | 20.69 | 22.79 | 18.19 | |
Earnings Yield |
5.29% | 4.32% | 7.17% | 4.23% | |
Free Cash Flow Yield |
(7.14%) | (2.77%) | (3.62%) | (3.40%) | |
Revenue per Share |
6.63 | 6.48 | 6.03 | 6.16 | |
Operating CF per Share |
2.48 | 3.88 | 1.78 | 2.20 | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.02) | |
Free Cash Flow per Share |
2.48 | 3.86 | 1.77 | 2.18 | |
Cash per Share |
9.68 | 12.82 | 13.76 | 4.60 | |
Shareholders Equity per Share |
8.70 | 9.51 | 9.74 | 9.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.70 | 9.51 | 9.74 | 9.61 | |
Free Cash Flow |
78.25 | 122.36 | 56.84 | 70.83 | |
Working Capital |
160.94 | 251.38 | 310.70 | 18.15 | |
Capital Expenditures |
(0.19) | (0.69) | (0.27) | (0.50) | |
Net Current Asset Value |
(718.65) | (663.75) | (593.86) | (1,215.87) | |
EV/EBIT |
10.24 | 10.41 | 7.53 | 13.45 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
15.05% | 8.26% | 7.49% | (7.53%) | |
Price to Operating Income |
7.04 | 8.17 | 5.62 | 7.46 | |
| Other line items | |||||
Average Receivables |
231.20 | 219.93 | 228.74 | 249.06 | |
Average Payables |
5.39 | 7.30 | 12.34 | 10.07 | |
Average Inventory |
38.04 | 38.24 | 39.98 | 75.71 | |
Average Assets |
1,621.24 | 1,660.21 | 1,641.67 | 1,864.21 | |
Average Common Equity |
254.54 | 265.26 | 273.43 | 272.06 |
Columns are period end dates